Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

In the world of biotechnology investing, companies often struggle to bring new drugs to market. Developing treatments for rare diseases can be incredibly expensive, and because these conditions ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is a biotech innovator who knows what ... to make a small, strategic investment in the firm back in 2023. But just because Nvidia and Cathie Wood have ...

CEO Tamer Mohamed told BIV he believes the investment climate in biotech is awful.Rob Kruyt, BIV “This is the worst funding climate for biotech in an entire generation,” he said.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Here are the best tax software deals to shop at Amazon.

Stocks started rising as the day unfolded with Fed Chair Jerome Powell reinforcing that interest rates remain in a "good ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take a drubbing. But at OSE Immunotherapeutics, which aims to prevent ...

Chicago Partners Investment Group LLC boosted its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing ...

SAN FRANCISCO – Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the ...

FNY Investment Advisers LLC owned 1.74% of Lixte Biotechnology worth $82,000 at the end of the most recent reporting period. Lixte Biotechnology Price Performance Shares of LIXT opened at $2.45 on ...

which offers comprehensive financial analysis and valuation metrics for informed investment decisions. In other recent news, MAIA Biotechnology has made significant strides in its clinical trials ...